Literature DB >> 16605277

Rationing of drugs for rare diseases.

Dyfrig Hughes.   

Abstract

Mesh：

Year:  2006        PMID： 16605277     DOI： 10.2165/00019053-200624040-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  7 in total

1.  Setting up an outcomes guarantee for pharmaceuticals: new approach to risk sharing in primary care.

Authors:  Stephen Chapman; Elly Reeve; Giri Rajaratnam; Richard Neary
Journal:  BMJ       Date:  2003-03-29

2.  Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis.

Authors:  Cathie L M Sudlow; Carl E Counsell
Journal:  BMJ       Date:  2003-02-15

3.  Ethical issues in funding orphan drug research and development.

Authors:  C A Gericke; A Riesberg; R Busse
Journal:  J Med Ethics       Date:  2005-03       Impact factor: 2.903

Review 4.  Orphan drugs and the NHS: should we value rarity?

Authors:  Christopher McCabe; Karl Claxton; Aki Tsuchiya
Journal:  BMJ       Date:  2005-10-29

Review 5.  No cure, no pay.

Authors:  Claus Møldrup
Journal:  BMJ       Date:  2005-05-28

Review 6.  Drugs for exceptionally rare diseases: do they deserve special status for funding?

Authors:  D A Hughes; B Tunnage; S T Yeo
Journal:  QJM       Date:  2005-10-03

Review 7.  The rule of rescue.

Authors:  John McKie; Jeff Richardson
Journal:  Soc Sci Med       Date:  2003-06       Impact factor: 4.634
  7 in total
  7 in total

1.  Access to orphan drugs despite poor quality of clinical evidence.

Authors:  Alain G Dupont; Philippe B Van Wilder
Journal:  Br J Clin Pharmacol       Date:  2011-04       Impact factor: 4.335

2.  Insurance companies' perspectives on the orphan drug pipeline.

Authors:  Robert Handfield; Josh Feldstein
Journal:  Am Health Drug Benefits       Date:  2013-11

Review 3.  A systematic review of moral reasons on orphan drug reimbursement.

Authors:  Bettina M Zimmermann; Johanna Eichinger; Matthias R Baumgartner
Journal:  Orphanet J Rare Dis       Date:  2021-06-30       Impact factor: 4.123

4.  Principles for consistent value assessment and sustainable funding of orphan drugs in Europe.

Authors:  Laura Gutierrez; Julien Patris; Adam Hutchings; Warren Cowell
Journal:  Orphanet J Rare Dis       Date:  2015-05-03       Impact factor: 4.123

5.  Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs.

Authors:  Katarzyna Kolasa; Krzysztof M Zwolinski; Zoltan Kalo; Tomasz Hermanowski
Journal:  Orphanet J Rare Dis       Date:  2016-03-10       Impact factor: 4.123

6.  New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes.

Authors:  Alice Varnava; Robert Bracchi; Karen Samuels; Dyfrig A Hughes; Philip A Routledge
Journal:  Pharmacoeconomics       Date:  2018-05       Impact factor: 4.981

Review 7.  Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.

Authors:  Tamás Zelei; Mária J Molnár; Márta Szegedi; Zoltán Kaló
Journal:  Orphanet J Rare Dis       Date:  2016-06-04       Impact factor: 4.123
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.